Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”

Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”

Guardado en:
Detalles Bibliográficos
Autor principal: Wing H. Tong MD, PhD, MSc
Formato: article
Lenguaje:EN
Publicado: SAGE Publishing 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/f41bd29d6e82455ab3df20fd5589b2a6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f41bd29d6e82455ab3df20fd5589b2a6
record_format dspace
spelling oai:doaj.org-article:f41bd29d6e82455ab3df20fd5589b2a62021-11-05T22:33:44ZComment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”1533-033810.1177/15330338211049902https://doaj.org/article/f41bd29d6e82455ab3df20fd5589b2a62021-10-01T00:00:00Zhttps://doi.org/10.1177/15330338211049902https://doaj.org/toc/1533-0338Wing H. Tong MD, PhD, MScSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTechnology in Cancer Research & Treatment, Vol 20 (2021)
institution DOAJ
collection DOAJ
language EN
topic Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Wing H. Tong MD, PhD, MSc
Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”
format article
author Wing H. Tong MD, PhD, MSc
author_facet Wing H. Tong MD, PhD, MSc
author_sort Wing H. Tong MD, PhD, MSc
title Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”
title_short Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”
title_full Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”
title_fullStr Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”
title_full_unstemmed Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”
title_sort comment on “correlation of l-asp activity, anti-l-asp antibody, asn and gln with adverse events especially anaphylaxis risks in peg-asp-contained regime treated pediatric all”
publisher SAGE Publishing
publishDate 2021
url https://doaj.org/article/f41bd29d6e82455ab3df20fd5589b2a6
work_keys_str_mv AT winghtongmdphdmsc commentoncorrelationoflaspactivityantilaspantibodyasnandglnwithadverseeventsespeciallyanaphylaxisrisksinpegaspcontainedregimetreatedpediatricall
_version_ 1718444015041380352

Ejemplares similares